Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Ann Allergy Asthma Immunol. 2016 Dec;117(6):674–679. doi: 10.1016/j.anai.2016.09.448

Table 1.

Subject characteristics.

Asthma (n = 26) Control (n = 15) p value
Gender, Female, n (%) 20 (77%) 9 (60%) 0.17
Age (SD) 48.00 (13.89) 40.71 (11.40) 0.10
Race 0.01
White, n (%) 22 (84.6) 11 (73.3)
Black, n (%) 4 (16) 0
Asian, n (%) 0 4 (26.7)
Allergic rhinitis, n (%) 24 (92) 3 (20.0) < 0.001
Age at asthma diagnosis (SD) 25.88 (18.43)
Current ICS use, n (%) 24 (92)
Used systemic steroid in past year, n (%) 14 (56%)
Average courses of systemic steroid in past year (SD) 2.8 (3.1)
ACT score (SD) 18.9 (4.2)
FEV1 percent predicted (SD) 92.60 (13.64)
FEV1/FVC percent predicted (SD) 96.56 (10.43)

ICS = inhaled corticosteroid steroid.